Combination of recombinant xenogeneic endoglin DNA and protein vaccination enhances anti-tumor effects

Immunological Investigations

Volumn 36, Issue 4, 2007, Pages 423-440

  Tan, Guang Hong ^a   Li, Yue Nan ^a   Huang, Feng Ying ^a   Wang, Hua ^a   Bai, Rui Zhen ^a   Jang, Jie ^a  

^a HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Autoantibody; Cancer; Endoglin; Immunogene therapy; Interferon ; T lymphocyte

Indexed keywords

AUTOANTIBODY; ENDOGLIN; GAMMA INTERFERON; PLASMID DNA; RECOMBINANT PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; IMMUNIZATION; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; VACCINATION;

ANIMALS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; COLORECTAL NEOPLASMS; IMMUNIZATION SCHEDULE; INTERFERON TYPE II; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 34547894736     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130701361103     Document Type: Article

References (43)

1. Barbara, N. P., Wrana, J. L., Letarte, M. (1999). Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J. Biol. Chem. 274:584-594.
2. Bodey, B., Bodey, B. Jr., Siegel, S. E., Kaiser H. E. (1998). Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma. Anticancer Res. 18:2701-2710.
3. Burrows, F. J., Derbyshire, E. J., Tazzari, P. L., Amlot, P., Gazdar, A. F., King, S. W., Letarte, M., Vitetta, E. S., Thorpe, P. E. (1995). Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res. 1:1623-1634.
4. Cooney, E. L., McElrath, M. J., Corey, L., Hu, S. L., Collier, A. C., Arditti, D., Hoffman, M., Coombs, R. W., Smith, G. E., Greenberg, P. D. (1993). Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. U.S.A. 90:1882-1886.
5. Czerkinsky, C. C., Nilsson, L. A., Nygren, H., Ouchterlony, O., Tarkowski, A. (1983). A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Meth. 65:109-121.
6. Delogu, G., Li, A., Repique, C., Collins, F., Morris, S. L. (2002). DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect. Immun. 70:292-302.
7. Donnelly, J. J., Wahren, B., Liu, M. A. (2005). DNA vaccines: progress and challenges. J. Immunol. 175:633-639.
8. Doria-Rose, N. A., Haigwood, N. L. (2003). DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 31:207-216.
9. Duff, S. E., Li, C., Garland, J. M., Kumar, S. (2003). CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 17:984-992.
10. Fan, T. P., Jaggar, R., Bicknell, R. (1995). Controlling the vasculature: angiogenesis; anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci. 16:57-66.
11. Ferrara, N., Alitalo, K. (1999). Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5:1359-1364.
12. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:4-6.
13. He, Q. M., Wei, Y. Q., Tian, L., Zhao, X., Su, J. M., Yang, L., Lu, Y., Kan, B., Lou, Y. Y., Huang, M. J., Xiao, F., Liu, J. Y., Hu, B., Luo, F., Jiang, Y., Wen, Y. J., Deng, H. X., Li, J., Niu, T., Yang, J. L. (2003). Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J. Biol. Chem. 278:21831-21836.
14. Holmgren, L., Ambrosino, E., Birot, O., Tullus, C., Veitonmaki, N., Levchenko, T., Carlson, L. M., Musiani, P., Iezzi, M., Curcio, C., Forni, G., Cavallo, F., Kiessling, R. A. (2006). A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc. Natl. Acad. Sci. USA 103:9208-9213.
15. Jiao, J. G., Li, Y. N., Wang, H., Liu, Q., Cao, J. X., Bai, R. Z., Huang, F. Y. (2006). A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig. Liver Dis. 38:578-587.
16. Kanegane, C., Sgadari, C., Kanegane, H., Teruya-Feldstein, J., Yao, L., Gupta, G., Farber, J. M., Liao, F., Liu, L., Tosato, G. (1998). Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J. Leukocyte Biol. 64:384-392.
17. Kang, Y., Calvo, P. A., Daly, T. M., Long, C. A. (1998). Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii; a rodent malaria parasite. J. Immunol. 161:4211-4219.
18. Lastres, P., Letamendia, A., Zhang, H., Rius, C., Almendro, N., Raab, U., Lopez, L. A., Langa, C., Fabra, A., Letarte, M., Bernabeu, C. (1996). Endoglin modulates cellular responses to TGF-beta 1. J. Cell Biol. 133:1109-1121.
19. Letamendia, A., Lastres, P., Botella, L. M., Raab, U., Langa, C., Velasco, B., Attisano, L., Bernabeu, C. (1998). Role of endoglin in cellular responses to transforming growth factor-β. A comparative study with betaglycan. J. Biol. Chem. 273:33011-3019.
20. Li, Y., Wang, M. N., Li, H., King, K. D., Bassi, R., Sun, H., Santiago, A., Hooper, A. T., Bohlen, P., Hicklin, D. J. (2002). Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 195:1575-1584.
21. Loetscher, M., Gerber, B., Loetscher, P., Jones, S. A., Piali, L., Clark-Lewis, I., Baggiolini, M., Moser, B. (1996). Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184:963-969.
22. Martinez, X., Li, X., Kovarik, J., Klein, M., Lambert, P. H., Siegrist, C. A. (1999). Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice. Eur. J. Immunol. 29:3390-3400.
23. Matsuno, F., Haruta, Y., Kondo, M., Tsai, H., Barcos, M., Seon, B. K. (1999). Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res. 5:371-382.
24. Mosmann, T. R., Sad, S. (1996). The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138-146.
25. Myers, C. D. (1991). Role of B cell antigen processing and presentation in the humoral immune response. FASEB J. 5:2547-2553.
26. Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., Reisfeld, R. A. (2002). A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8:1369-1375.
27. Pertl, U., Luster, A. D., Varki, N. M., Homann, D., Gaedicke, G., Reisfeld, R. A., Lode, H. N. (2001). IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J. Immunol. 166:6944-6951.
28. Risau, W. (1997). Mechanisms of angiogenesis. Nature 386:671-674.
29. Romagnani, S. (1997). The Th1/Th2 paradigm. Immunol. Today 18:263-266.
30. Seon, B. K., Matsuno, F., Haruta, Y., Kondo, M., Barcos, M. (1997). Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin. Cancer Res. 3:1031-1044.
31. She, X., Matsuno, F., Harada, N., Tsai, H., Seon, B. K. (2004). Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int. J. Cancer 108:251-257.
32. Smith, J. G., Liu, X., Kaufhold, R. M., Clair, J., Caulfield, M. J. (2001). Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin. Diagn. Lab. Immunol. 8:871-879.
33. Song, M. K., Lee, S. W., Suh, Y. S., Lee, K. J., Sung, Y. C. (2000). Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice. J. Virol. 74:2920-2925.
34. Tabata, M., Kondo, M., Haruta, Y., Seon, B. K. (1999). Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies. Int. J. Cancer 82:737-742.
35. Tan, G. H., Tian, L., Wei, Y. Q., Zhao, X., Li, J., Wu, Y., Wen, Y. J., Yi, T., Ding, Z. Y., Kan, B., Mao, Y. Q., Deng, H. X., Li, H. L., Zou, C. H., Fu, C. H. (2004). Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. Int. J. Cancer 112:701-706.
36. Tan, G. H., Wei, Y. Q., Tian, L., Zhao, X., Yang, L., Li, J., He, Q. M., Wu, Y., Wen, Y. J., Yi, T., Ding, Z. Y., Kan, B., Mao, Y. Q., Deng, H. X., Li, H. L., Zhou, C. H., Fu, C. H., Fei, X., Zhang, X. W. (2004). Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur. J. Immunol. 34:2012-2021.
37. Tannenbaum, C. S., Tubbs, R., Armstrong, D., Finke, J. H., Bukowski, R. M., Hamilton, T. A. (1998). The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161:927-932.
38. Thorpe, P. E. (2004). Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10:415-427.
39. Wang, J. M., Kumar, S., Pye, D., van Agthoven, A. J., Krupinski, J., Hunter, R. D. (1993). A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer 54:363-370.
40. Wang, S., Arthos, J., Lawrence, J. M., Van Ryk, D., Mboudjeka, I., Shen, S., Chou, T. H., Montefiori, D. C., Lu, S. (2005). Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J. Virol. 797933-7937.
41. Wei, Y. Q., Huang, M. J., Yang, L., Zhao, X., Tian, L., Lu, Y., Shu, J. M., Lu, C. J., Niu, T., Kang, B., Mao, Y. Q., Liu, F., Wen, Y. J., Lei, S., Luo, F., Zhou, L. Q., Peng, F., Jiang, Y., Liu, J. Y., Zhou, H., Wang, Q. R., He, Q. M., Xiao, F., Lou, Y. Y., Xie, X. J., Li, Q., Wu, Y., Ding, Z. Y., Hu, B., Hu, M., Zhang, W. (2001). Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc. Natl. Acad. Sci. USA 98 11545-11550.
42. Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., Felgner, P. L. (1990). Direct gene transfer into mouse muscle in vivo. Science 247:1465-1468.
43. Xiang, R., Mizutani, N., Luo, Y., Chiodoni, C., Zhou, H., Mizutani, M., Ba, Y., Becker, J. C., Reisfeld, R. A. (2005). A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 65:553-561.